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Abstract
The synthesis and characterization of two generation-4 polyamidoamine (PAMAM) dendrimers
with S-nitrosothiol exteriors are reported. The hyperbranched macromolecules were modified with
either N-acetyl-D,L-penicillamine (NAP) or N-acetyl-L-cysteine (NACys) and analyzed via 1H
and 13C-NMR, UV absorption spectroscopy, MALDI-TOF mass spectrometry, and size exclusion
chromatography. Treatment of the dendritic thiols with nitrite solutions yielded the corresponding
S-nitrosothiol nitric oxide (NO) donors (G4-SNAP, G4-NACysNO). Chemiluminescent NO
detection demonstrated that the dendrimers were capable of storing ~2 μmol NO·mg−1 when
exposed to triggers of S-nitrosothiol decomposition (e.g., light and copper). The kinetics of NO-
release were found to be highly dependent on the structure of the nitrosothiol (i.e., tertiary vs.
primary) and exhibited similar NO-release characteristics to classical small molecule nitrosothiols
reported in the literature. As demonstration of utility, the ability of G4-SNAP to inhibit thrombin-
mediated platelet aggregation was assayed. At equivalent nitrosothiol concentrations (25 μM), the
G4-SNAP dendrimer resulted in a 62% inhibition of platelet aggregation, compared to only 17%
for the small molecule NO donor. The multivalent NO storage, the dendritic effects exerted on
nitrosothiol stability and reactivity, and the utility of dendrimers as drug delivery vehicles
highlight the potential of these constructs as clinically useful S-nitrosothiol-based therapeutics.
Introduction
S-nitrosothiols (RSNO) are ubiquitous in human physiology and are involved in a multitude
of cell signaling cascades.1 Endogenously, nitrosothiols are formed either via the reaction of
free thiols with N2O3, the reactive nitrogen species formed following the auto-oxidation of
nitric oxide (NO), or through a host of redox mechanisms involving metabolites of NO and
transition metal centers.1 Nitrosation of cysteine residues on serum albumin and the
nitrosation/nitrosylation of deoxyhemoglobin account for a large portion of the 1.8 μM
nitrosothiol concentration in blood.2, 3 As the main carriers of NO in vivo, nitrosothiols
regulate several biological processes including vasodilation, platelet activation,
neurotransmission, and tissue inflammation.1, 4, 5 Synthetic nitrosothiol NO donors such as
S-nitroso-N-acetyl-DL-penicillamine (SNAP) have been employed to better understand the
many complicated roles of NO in regulatory biology,6 with the most notable instance
including the discovery by Ignarro and co-workers that NO is the vascular endothelial
derived relaxation factor.7
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Numerous reports have outlined the therapeutic potential of nitrosothiol adducts, including
their toxicity toward cancerous cells,8, 9 antimicrobial activity,10–13 and cardioprotective
effects during ischemia/reperfusion injury.14–16 Perhaps the most documented clinical
application of S-nitrosothiols is as anti-platelet agents, whereby RSNOs inhibit platelet
aggregation without affecting vascular tone.17–22 Despite the promising therapeutic potential
of nitrosothiols, the inability to target NO to a specific site of action and the rapid systemic
clearance associated with small drug molecules has seriously hindered the clinical
development of nitrosothiol therapeutics. In response, several macromolecular nitrosothiol
NO donors have been synthesized to store NO and expand RSNO delivery options. For
example, S-nitrosocysteine polymer conjugates have been utilized as materials to aid in the
prevention of thrombosis/restenosis23, 24 and for the delivery of RSNOs in topical
biomedical applications.25 Meyerhoff and co-workers have employed nitrosothiol-modified
fumed silica particles as polymer dopants and demonstrated tunable NO-release from
hydrophobic polymers as a function of light.26 Protein-based nitrosothiol delivery vehicles
have also been explored as a strategy to extend the systemic half-lives of exogenous RSNO
donors and to aid in the treatment of circulation disorders.27–30
The use of polymeric and protein drug conjugates have led to significant strides in NO
delivery. Unfortunately, the NO storage capacity (pmol – nmol NO·mg−1) and/or the
number of sites for covalent attachment of additional functionalities remain limited.
Previous work from our laboratory has described the synthesis of diazeniumdiolate-modified
polypropylenimine dendrimer conjugates as macromolecular NO donors capable of storing
up to 5.6 μmol NO·mg−1 with NO-release kinetics dependent on dendrimer structure.31
Dendrimers represent attractive vehicles for NO loading because of their multivalent
exterior and its ability to not only to store large amounts of NO, but its capacity for
additional functionalities for increasing drug specifity.3132, 33 Herein, we report the
synthesis and characterization of two thiol-derivatized generation 4 polyamidoamine
(PAMAM) dendrimers capable of storing up to 2 μmol NO·mg−1 dendrimer when converted
to the corresponding nitrosothiol NO donors (Figure 1). S-nitrosothiols have received
considerable attention as the primary NO carriers in blood and their decomposition
mechanisms represent alternative strategies for controlled NO-release, albeit under
conditions distinct from diazeniumdiolates.31 The effect of SNAP-modified G4 dendrimer
on platelet aggregation is explored and compared to SNAP, the analogous small molecule
nitrosothiol, to confirm the retention of biological activity of dendrimer bound RSNOs.
Results and Discussion
Synthesis of Thiol Modified Dendrimers
G4-NAP (2)—Previously, Wang and co-workers developed a strategy toward increasing
the cellular uptake of S-nitrosothiols in human prostate cancer cells by first reacting amino
sugars with the cyclized thiol, 3-acetamido-4,4-dimethylthietan-2-one.9, 34 Utilizing a
similar approach to modify the exterior amines of a generation 4 PAMAM dendrimer, N-
acetyl-D,L-penicillamine was cyclized in low yields (29%) to 1 (3-acetamido-4,4-
dimethylthietan-2-one) with acetic anhydride and pyridine.35 The G4-PAMAM dendrimer
was then modified with thiol in one step via the reaction of the surface primary amines with
thiolactone (1) (Scheme 1). Following dialysis and lyophilization, the extent of G4-NAP (2)
modification was assessed via 1H NMR and the Ellman’s assay36, 37 to quantify the number
of free thiols attached to the dendrimer scaffold. The integrated intensity of the protons on
the geminal methyl substituents adjacent to the terminal thiols (C(CH3)SH) was compared to
the interior methylene protons inside the dendrimer to confirm attachment of the N-acetyl-
D,L-penicillamine groups (NMR spectra provided in Supporting Information). The number
of immobilized thiol groups was calculated to be 63 thiols (NMR), correlating well with
number of free thiols assayed on the dendrimer surface 62.1 ± 2.2 (Ellman’s assay).
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Size exclusion chromatography (SEC) was employed to assess both the molecular weight
and purity of the dendrimer conjugate. SEC revealed negligible low molecular weight
impurities following the synthesis and isolation of product. However, a significant
population of high molecular weight species was observed (Supporting Information).
Although the N-acetyl-D,L-penicillamine-modified dendrimer contained 20% multimer by
weight, the majority of the sample was the fully reduced 23,700 MW G4-NAP. Multimer
formation was attributed to the presence of intra- and/or inter-dendrimer disulfide crosslinks
but dendrimer conjugates were not stored/prepared under reducing conditions as such
chemistry proved incompatible with subsequent S-nitrosothiol formation. High resolution
MALDI-TOF mass spectrometry of 2 prepared in a sinapinic acid matrix indicated that the
molecular weight of G4-NAP was 23,000 g/mol, further validating the SEC data. A
summary of dendrimer characterization data is provided in Table 1.
G4-NACys (6)—Although the synthetic procedure described above yields G4-NAP thiol-
modified dendrimer in two steps, the approach results in a 100% thiol-modified exterior
surface that may hinder the synthesis of multifunctional NO delivery vehicles. The opening
of the thiolactone ring results in the formation of highly reactive thiols. Further conjugation
chemistry to attach additional functionalities on the dendrimer would necessitate binding to
the free thiols, reducing NO storage capacity. Thus, protected S-trityl-N-acetyl-L-cysteine
was employed as a precursor to nitrosothiol formation allowing for future orthogonal
coupling of ligands (e.g., folic acid, fluorescent dyes) to the dendritic exterior, followed by
deprotection of the thiol which may then be converted to the RSNO donor. A similar
approach was described previously to synthesize cysteine-modified poly(propyleneimine)
dendrimers to allow native chemical ligation of both oligopeptides and recombinant
proteins.38 N-acetyl-L-cysteine as trityl-protected using a mixture of triphenyl methanol and
BF3-etherate in concentrated acetic acid (Scheme 2).26 Upon neutralization with saturated
sodium acetate and extraction in ether, the white solid 4 was isolated (85% yield). Following
activation to the succinimidyl ester 5, the S-trityl-N-acetyl-L-cysteine-protected thiol was
coupled to G4 PAMAM by reaction with the dendrimer’s exterior amines. The trityl
protected dendrimer conjugate was then treated with trifluoroacetic acid to remove the trityl
protecting groups. The dendrimer product was dissolved in water, washed with ether, and
lyophilized to yield 6 (G4-NACys) as a white flaky solid (67%).
Size exclusion chromatography (SEC) of G4-NACys resulted in similar chromatograms as
described above for G4-NAP, whereby 16% high molecular weight species was detected
arising from dendrimers crosslinked via disulfide bridges (Supporting Information). The
molecular weight of the higher molecular weight impurity calculated from light scattering
data was 44,550 g/mol, approximately double the mass of the dominate G4-NACys single
dendrimer (20,630 g/mol), suggesting dimer formation. MALDI-TOF mass spectrometry
confirmed that the molecular weight of the prominent G4-NACys species was 21,200 g/mol.
consistent with molecular weight observed in SEC. This protection/deprotection strategy
employed herein may be useful in the future synthesis of multifunctional NO-releasing
dendrimers as it allows for orthogonal coupling of multiple agents to the dendrimer scaffold
without interfering with the thiol structure.
Conversion to S-nitrosothiol dendrimers—To convert the thiols to S-nitrosothiols,
acidified nitrite solutions were employed. When compared to their alkyl nitrite counterparts,
such solutions are faster and more efficient at nitrosothiol formation.39 The tertiary thiol
(G4-NAP) and primary thiol (G4-NACys) dendrimers provide macromolecules with
different thiol stabilities and chemical properties when converted to the corresponding NO
donors. Dendrimer 2 (G4-NAP) was dissolved in a 50:50 mixture of MeOH/1M HCl and
treated with NaNO2 on ice. The acidified nitrite solution rapidly turned green indicating S-
nitroso-N-acetyl-D,L-penicillamine (SNAP) formation. Following removal of the solvent
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under reduced pressure at 0 °C, the nitrosothiol-modified dendrimer was reconstituted in
cold ethanol and removed from the salt byproducts via filtration. The ethanol was again
removed at 0 °C to yield 3 as a green polymer film in 92% yield. Low temperatures and
shielding from light were maintained throughout the isolation procedure to prevent NO
release and the formation of insoluble aggregates.
Primary nitrosothiol adducts (e.g., S-nitroso-cysteine) have been historically difficult to
isolate following nitrosothiol formation due to poor RSNO stability.40 Similarly, the
acidified nitrite approach described above proved troublesome when working with the G4-
NACys dendrimer. Removal of the solvent led to an insoluble polymerized network of thiol
dendrimers. As an alternative strategy to convert free thiols of 6 to S-nitrosothiol NO
donors, the dendrimer was dissolved in a methanol/water solution, added to 200 mL of
stirring toluene, and treated with isopentyl nitrite.26 After reaction with the organic nitrite
source for 2 h, a pink precipitate was observed on the walls of the flask. The precipitate was
removed via filtration and dried under vacuum to yield 7 (G4-NACysNO, 75%). As S-
nitrosothiol dendrimer conjugates proved susceptible to thermal decomposition, low
temperatures were employed during all isolation steps to minimize NO donor degradation
and prevent dendrimer disulfide cross linking.
G4-SNAP and G4-NACysNO nitrosothiol dendrimer conjugates possessed characteristic
absorption maxima governed by the tertiary or primary thiol structures (Figure 2). The G4-
SNAP dendrimer had an intense broad band at 341 nm (π→π*) and a weaker absorption
maxima at 596 nm (n→π*) giving the anti conformer of the tertiary thiol its greenish
color.41, 42 The G4-NACysNO conjugate had a similar π→π* transition at 320 nm and a
blue shifted n→π* transition at 545 nm.
Characterization of NO Storage through RSNO Decomposition
G4-SNAP and G4-NACysNO provide two contrasting macromolecular nitrosothiol donors
with NO-release properties dependent on NO donor structure. Chemiluminescent detection
of NO released following RSNO decomposition was employed to characterize the NO-
loading efficiency of these new NO release scaffold and study the effects of nitrosothiol
structure on NO release.
Copper mediated NO-release—A major mechanism of S-nitrosothiol decomposition is
mediated via the Cu+/Cu2+ redox couple and copper containing enzymatic metal
centers.5, 42, 43 Previous work has confirmed that the breakdown reaction in solution
proceeds via the reduction of Cu2+ by trace thiolate anion to yield Cu+ that subsequently
reduces RSNO compounds to initiate NO release.43,44 This reaction does not proceed
through a thiyl radical intermediate (Scheme 3A). Aqueous solution containing copper
bromide (CuBr2) was utilized to decompose the S-nitrosothiol dendrimer conjugates to NO
and corresponding dendritic disulfides. All copper mediated NO-release testing was
performed in phosphate buffered saline (PBS, pH = 7.4) at physiological temperature (37
°C) and in the dark.
The real-time NO-release profiles for copper initiated NO release from G4-SNAP (3) and
G4-NACysNO (7) are shown in Figure 3 (A and B). The tertiary S-nitrosothiols of G4-
SNAP exhibited a more rapid release of NO as evidenced by the maximum intensity of NO
release, [NO]m. For example at 1 mM Cu2+, the [NO]m for G4-SNAP was 92,100 ppb/mg
whereas the [NO]m for G4-NACysNO was only 26,200 ppb/mg. The kinetics of G4-SNAP
dendrimer decomposition exhibited small changes as a function of Cu2+ concentration with
0.2 and 0.6 mM Cu2+ possessing nearly identical NO-release profiles. However, [NO]m of
the primary S-nitrosothiol terminated dendrimer G4-NACysNO scaled with copper
concentration (Figure 3B, Table 2) but never reaching the same intensity as the G4-SNAP
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NO-release. The full set of kinetic parameters including the time required to reach the
maximum flux (tm) and half life of NO-release (t1/2) are given in Table 2. Despite the
variable NO-release kinetics, the same level of total NO released (t[NO], Table 1) was
achieved regardless of the copper concentration corresponding to 79% NO-storage
efficiency for the synthesis of the G4-SNAP dendrimer and 87% for G4-NACysNO.
In the development of S-nitrosothiol therapeutics, copper-mediated NO-release holds
minimal promise due the lack of free-circulating Cu2+. Ascorbate has often been mistaken as
another trigger to initiate S-nitrosothiol decomposition as its concentration in the blood is
appreciable (81 μM).45 However, ascorbate mediates NO release only through the reduction
of trace metal ions in solution which then promote NO release.46 In the presence of EDTA,
the dendritic nitrosothiols exhibited no increase in the rate of NO release upon exposure to
concentrations of ascorbate up to 2 mM, suggesting that ascorbate is not a viable initiator of
S-nitrosothiol dendrimer decomposition (data not shown). Of note, this does not rule out the
possibility of other agents capable of facilitating the one-electron reduction to release NO
for future therapeutic applications.5
Photoinitiated NO-release—Photoinitiated NO-release is another well-characterized
mechanism of RSNO decomposition.47 Irradiation at either RSNO absorption maximum has
been shown to result in homolytic cleavage of the S-N bond to yield NO and a thiyl radical
in a process that is approximately first-order.47 Electron paramagnetic resonance spectra of
spin-trapped thiyl radicals have been reported as concrete evidence for the phototriggered
homolysis of the S-N bond.48 Photolysis of dendrimer nitrosothiol conjugates with a broad
spectrum white light source also yielded a dendritic thiyl radical and NO (Scheme 3B). The
reaction is further propagated when the resulting thiyl radical reacts with a neighboring
RSNO branch to produce a disulfide and additional NO (Scheme 3B). Consistent with
previously reported observations for nitrosothiol decomposition,26 the NO-release from G4-
SNAP and G4-NACysNO dendrimers was dependent on light intensity and followed first
order decay (Table 2). The nitrosothiol-modified dendrimers were also extremely responsive
to the light source and exhibited a clear on/off behavior when the light was removed. The
behavior of G4-SNAP exposed to repeat cycles of 2 min light irradiation followed by 3 min
of darkness is shown in Figure 4A. When the 200 W light source was removed, the signal
rapidly returned to baseline. The intensities of [NO]m slowly declined during subsequent
irradiations, as expected with the depletion of RSNO. Homolytic cleavage of the S-N bond
may also result via thermal decomposition of RSNO donors, albeit at a much slower rate.
The difference between the slow thermal decomposition of G4-SNAP dendimer (9.31 pmol
NO·mg−1·s−1, indicated by the asterisk) and the rate of NO-release upon exposed to 200 W
light is shown in Figure 4B.
Overall, G4-SNAP dendrimer was more susceptible to changes in light intensity than G4-
NACysNO. Both dendrimers resulted in similar half-lives and [NO]m at 200W (Table 2) but
the most significant kinetic variation between the two conjugates was observed at early
periods (<30 min). The initial rates of phototriggered decomposition for the G4-NACysNO
dendrimer were also slower than the G4-SNAP conjugate as indicated by the time required
to reach the maximum flux (tm) (Table 2). This initial delay and lower intensity of G4-
NACysNO release is explained by a “cage effect” imposed by the G4-NACysNO dendrimer
conjugate whereby a more compact solution structure results in the increased frequency of
geminate radical pair recombination and slows the initial rates of NO release.49,50 Indeed,
Shishido et al. have demonstrated that photogeneration of NO from S-nitroso-N-
acetylcysteine in a PEG matrix resulted in a 22-fold decrease in the intial rate of RSNO
decomposition when compared to normal aqueous media.50 Additionally, the PEG
microenvironment reduced the rates of thermal decomposition at room temperature. The
increased stability of the macromolecular G4-NACysNO structure suggests a “dendritic
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effect” on phototriggered NO release, whereby the G4-NACysNO solution structure may be
more compact that G4-SNAP and thus lead to increased rates of radical recombination. This
“cage effect” may be manipulated for future biomedical applications by increasing
dendrimer size (G5–G8) or through the attachment of poly(ethylene glycol) functionalities
to the dendrimer exterior leading to increased storage and handling of S-nitrosothiols.
S-Nitrosothiol Inhibition of Platelet Aggregation
Free nitric oxide inhibits platelet aggregation via a guanylyl-cyclase dependent
mechanism.17 However, the signaling actions of RSNOs are not completely dependent on
the release of free NO and the mechanism by which they deliver NO to platelets is much
debated.51 Transnitrosation5 between RSNO and membrane bound protein thiols provides a
mechanism for direct cellular communication and transfer of NO that does not proceed
through a thiyl radical intermediate. Transnitrosation can be defined as the transfer of the
nitroso functional group from a nitrosothiol donor to a free thiol as shown in Scheme 3C.
Indeed, transnitrosation reactions between exogenous NO donors and proteins on the platelet
surface are well known.52–54
The efficacy of the G4-SNAP dendrimer conjugate at inhibiting thrombin-catalyzed platelet
aggregation was examined to compare the biological activity of the RSNO-modified
dendrimers to free small molecule SNAP. The platelet aggregation of small molecule SNAP
and G4-SNAP dendrimer as monitored by the loss of turbidity in solution using an
aggregometer is shown in Figure 5. A dose-dependent inhibition of platelet aggregation was
observed for the SNAP NO donor with 75% inhibition observed at 100 μM SNAP (Figure
5A). Solutions prepared with equimolar RSNO functionalites on G4-SNAP dendrimer
(estimated at 64 RSNO per mol dendrimer) exhibited a pronounced inhibition of thrombin-
mediated aggregation regardless of dendrimer concentration (Figure 5B). At 25 μM SNAP
functionality on the G4-SNAP conjugate (390 nM dendrimer), a 62% reduction in
aggregation was observed compared to only a 17% inhibition for 25 μM small molecule
SNAP. The abundance of RSNO donors localized on the dendritic structure was far more
effective than small molecule SNAP at reducing platelet aggregation. We speculate that the
dendritic structure may facilitate interaction with the platelet surface effectively creating a
greater local concentration of RSNO moieties and thereby lowering the effective dose of
SNAP required to elicit the same therapeutic effect as free SNAP in solution. Control G4-
NAP (2) and N-acetyl-D,L-penicillamine without NO were also evaluated at concentrations
up to 100 μM and showed minimal effects on platelet aggregation. The inactivity of the thiol
controls and the absence of SNAP decomposition triggers in these experiments (e.g., light,
copper, etc.) indicate that the observed inhibition of platelet aggregation was mediated via
transnitrosation and any resulting nitrogen species derived from transnitrosation. 52–54
Conclusions
The synthesis of thiol-modified G4-PAMAM dendrimers and their conversion to S-
nitrosothiol NO donors represents a new class of NO-releasing dendrimer constructs. The
dendrimer scaffold enables the enhanced storage of RSNO donors relative to previously
reported nitrosothiol delivery vehicles. For example, G4-PAMAM (MW 14,215 g/mol) has
64 surface sites for NO loading (Figure 1) compared to only 14 for a fully reduced serum
albumin conjugate (MW ~66,000g/mol).27 The G4-SNAP and G4-NACysNO dendrimers
effectively stored and released 1.7 ± 0.2 and 2.1 ± 0.2 μmol NO·mg−1, respectively, when
using known triggers of nitrosothiol decomposition such as Cu2+ or light. S-nitrosothiol
modified dendrimers serve as large storage reservoirs of NO and may thus prove useful for
polymeric topical wound dressing formulations, for example. When exposed to a broad
spectrum white light source, the rapid burst of NO from such dressings may release NO at
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concentrations necessary to kill bacteria that cause infection.10,11 Indeed, NO has recently
been shown to kill even the most robust bacteria, including methicillin-resistant S. aureus
(MRSA).10
The ability to undergo transnitrosation reactions with biological substrates (e.g., platelets)
allows for careful control of NO-release previously unattainable with diazeniumdiolate-
modified dendrimers.31 Via transnitrosation, the anti-platelet activity of G4-SNAP
dendrimer was 45% more effective at preventing platelet aggregation at 25 μM than the
corresponding small molecule NO donor SNAP. These RSNO dendrimers may serve as
stable carriers of NO in vivo but targeting NO to specific tissues or cell types is challenging.
The biggest advantage of the dendritic scaffold over other potential RSNO drug delivery
vehicles is the ease in which multiple surface functionalities may be appended to the
dendrimer exterior. For example, Baker and co-workers have synthesized dendrimers
containing the methotrexate (an anti-cancer drug), fluorescent probes for imaging, and folic
acid residues for targeting the delivery vehicle to cancerous tissue in vivo.55 Work is
underway in our laboratory to synthesize multi-functional dendrimer conjugates that
integrate the recent advancements in nanoparticle drug delivery with the current mechanistic




Generation 4 polyamidoamine dendrimer (G4-PAMAM), N-acetyl-L-cysteine, trityl
chloride, triphenylmethanol, boron trifluoride diethyl etherate (BF3-etherate),
isopentylnitrite, L-glutathione, ethylenediamine tetraacetate (EDTA), N-hydroxy
succinimide, dicyclohexylcarbodiimide, 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB), and
triethylamine were purchased from the Aldrich Chemical Company (Milwaukee, WI). N-
acetyl-D,L-penicillamine and anhydrous sodium bisulfate were purchased from Fluka.
Sodium nitrite and anhydrous pyridine were purchase from Acros Organic. All other
common laboratory salts and solvents were purchased from Fisher Scientific. Water was
purified using a Millipore Milli-Q gradient A-10 purification system (Bedford, MA).
Spectra/Por® Float-A-Lyzers® were purchased from Spectrum Laboratories Inc. (Rancho
Dominguez, CA). Absorption spectra were recorded on a Perkin Elmer Lambda 40 UV-Vis
spectrophotometer (Norwalk, CT). Nuclear magnetic resonance (NMR) spectra were
collected in CDCl3 and D2O (Sigma-Aldrich) using a 400-MHz Bruker Nuclear Magnetic
Resonance spectrometer. Mass spectra were acquired on a Kratos MALDI AXIMA CFR
plus instrument in linear mode (2 GHz), power 160. Dendrimer samples for mass analysis
were prepared at a concentration of 2 mg/mL in a sinapinic acid matrix, 1:1 CH3CN/TFA
(0.05%). Size exclusion chromatography was performed on a Wyatt DAWN EOS light
scattering instrument interfaced with an Amersham Biosciences Akta FPLC system
equipped with a Wyatt Optilab refractometer and Wyatt dynamic light scattering module.
Nitric oxide release was measured using a Sievers 280i Chemiluminesce Nitric Oxide
Analyzer (Boulder, CO) as described previously.56
Synthesis and characterization of dendrimer conjugates
Complete synthetic details for nitrosothiol modified dendrimer conjugates and all
characterization data may be found in Supporting Information.
NO-release testing of nitrosothiol containing dendrimers
Chemiluminescence57 was employed to quantify the NO released from the S-nitrosothiol
dendrimer conjugates upon exposure to various triggers previously identified to initiate
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nitrosothiol decomposition in the literature (e.g., copper, light, ascorbate and temperature).
Total NO release (t[NO], μmol NO/mg) was used to quantify storage efficiency of the thiol-
modified dendrimers. The percent yield values in Table 1 were calculated based on 64
theoretical amines on the dendrimer starting material, the successful conversion of these
amines to 64 surface thiols, and their modification to 64 S-nitrosothiol moieties. Aliquots
(10 μL) of the dendrimer products in 5 mM EDTA in water for G4-NACysNO or EtOH for
G4-SNAP were added to a reaction flask containing 10 mM phosphate buffered saline (PBS,
pH=7.4) with 5 mM EDTA to chelate trace copper in the media. A large excess of EDTA
was required to completely remove initial bursts of NO-release attributed to Cu2+ ion
impurities in solution. Chelator was not employed during Cu2+-mediated NO-release testing.
All NO-release testing was conducted at physiological temperature (37 °C) except when
testing the rates of thermal decomposition. Dendrimer concentrations in the 30 mL reaction
flask ranged from 300–700 nM. The chemiluminescence analyzer was calibrated with NO
gas (24.1 ppm). The value for converting instrument response (ppb) to moles of NO was
obtained via the conversion known concentrations of nitrite standards to NO in a 0.1 M
KOH/H2SO4 solution (1.34 × 10 −13 moles NO/ppb). During photo-initiated NO release
experiments 60, 100, or 200 W bulbs were employed (Crystal Clear, General Electric). The
light source was positioned ~5 inches from the sample. Copper solutions were prepared by
dissolving CuBr2 in the running buffer (200 –1000 μM) prior to degassing the sample.
Chemiluminescence data for the NO-releasing dendrimers were represented in two graphical
forms or plots: 1) chemiluminescence response in ppb NO/mg dendrimer versus time; and,
2) the total amount of NO-release (t[NO], μmol NO/mg) versus time. Kinetic parameters
including the maximum flux of NO release ([NO]m) and the time required to reach that
maxima (tm) were obtained from plot 1 while the half-life (t1/2) of NO release was
determined from plot 2.
Platelet rich plasma isolation
Fresh platelets were prepared from venous blood drawn from healthy volunteers in
accordance with institutional guidelines. Whole blood (42.5 ml blood to 7.5 ml
anticoagulant) was drawn into a syringe containing citrate (3.2% by weight, pH = 7.4).
Platelet rich plasma (PRP) was obtained by centrifugation (200 × g, 20 minutes) at 25 °C.
The platelet rich plasma was centrifuged at 1000 × g for 10 min at room temperature to
obtain a platelet pellet. The platelet pellet was suspended in the original volume of Tyrode’s
buffer (without divalent cations, 137 mM NaCl, 3 mM KCl, 3 mM sodium phosphate, 2 mM
sodium bicarbonate, 5 mM glucose, 10 mM Hepes) and centrifuged as in the last step. The
final pellet was suspended in Tyrode’s buffer at 200,000 platelets/μL, as measured with a
Heska hematological analyzer.
Platelet aggregation studies
Aliquots of platelets in Tyrode’s buffer at 200,000 platelets/μl were placed in the optical
cuvettes in the aggregometer (Chrono-Log Whole Blood Aggregometer) and equilibrated to
37 °C while stirring. DMSO stocks of NO donor compounds (or neat DMSO as a carrier
control) were diluted 1/100 into the stirred platelet suspensions and allowed to incubate for
15 min. Aggregation reactions were initiated by adding 100 × stocks of CaCl2 for a final
calcium concentration of 10 mM and 100 NIH unit/ml stocks of human α-thrombin for a
final concentration of 1 NIH unit/ml. The degree to which test agents inhibited thrombin-
mediated platelet aggregation was estimated from the final extent of aggregation (turbidity
change) at 25 min. The turbidity changes of each sample were normalized to the turbidity
observed for the DMSO carrier. Dose response curves represent the average of two
independent sets of measurements on different days with different blood donors tested n=3
Stasko et al. Page 8













times each. The error bars represent standard error of the mean between the two sets of
measurements.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Generation 4 PAMAM containing a completely modified exterior (64 thiols) of S-nitroso-N-
acetyl-D,L-penicillamine (G4-SNAP) or S-nitroso-N-acetylcysteine (G4-NACysNO).
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UV-Vis absorption spectra of G4-SNAP and G4-NACysNO dendrimer conjugates (2 mg/
mL in EtOH solutions).
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A) NO-released from 3 (G4-SNAP) exposed to 200 μM (---), 600 μM (…...), and 1 mM (—)
Cu2+ in PBS buffer at 37 °C. Additionally, two parameters used to anotate the NO-release
kinetics are defined: maximum flux of NO-release ([NO]m) in ppb/mg and time required to
reach the maximum (tm). B) NO-released from 7 (G4-NACysNO) exposed to 200 μM (---),
600 μM (…...), and 1 mM (—) Cu2+ in PBS buffer at 37 °C. C) Total NO-release curves of
G4-SNAP and G4-NACysNO illustrating the kinetic difference between tertiary and
primary nitrosothiol decomposition at 200 μM Cu2+. Two parameters used to describe NO-
release data are also defined graphically: total NO released (t[NO]) in μmol NO/mg
dendrimer and half-life (t1/2) of NO-release. (Data is truncated at 12 h, despite the increase
of G4-NACysNO-release for up to 15 h.)
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A) Phototriggered on/off behavior of G4-SNAP dendrimer conjugate (3) at 200 W. Sample
was irradiated at 2 min intervals followed by 3 min of darkness B) Permanent irradiation of
G4-SNAP at 200 W illustrating the long first order decay over several hours. The * signifies
thermal NO-release at 37 °C prior to exposing the dendrimer to the light source. (Inset: Total
NO release curve for G4-SNAP.)
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Human thrombin-initiated platelet aggregation in the presence of A) SNAP small molecule
or B) G4-SNAP dendrimer conjugate. Turbity changes of the 0–100 uM RSNO donors were
normalized to the DMSO signal (100%). C) Normalized percent aggregation for SNAP
(gray) and G4-SNAP dendrimer (white). Control represents aggregation in 100 μM thiol
control (N-acetyl-D,L-penicillamine or G4-NAP. Error is represented as standard error of
the mean for two independent blood samples tested n=3 times each.
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Synthesis of S-nitrosothiol modified generation 4 PAMAM dendrimer, G4-SNAP (3).
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Synthesis of G4-NACysNO, S-nitrosothiol modified generation 4 PAMAM dendrimer.
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Mechanisms of nitrosothiol decomposition and NO release
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